The global HPV Testing and Pap Test Market was valued at around US$ 2.2 Billion in 2021. With a projected CAGR of 19.3% for the next ten years, the market is likely to reach a valuation of approximately US$ 15 Billion by the end of 2032.
| Attributes | Details |
|---|---|
| HPV Testing and Pap Test Market Size (2021A) | US$2.2 Billion |
| Estimated Market Value (2022E) | US$2.6 Billion |
| Forecasted Market Value (2032) | US$15 Billion |
| Global Market Growth Rate (2022 to 2032) | 19.3% CAGR |
| United States Forecasted Market Value (2032) | US$ 5.9 Billion |
| USA Growth Rate(2022 to 2032) | 20.4% CAGR |
| Key Companies Covered |
|
Future Market Insights’ analysis reveals that most of the HPV Testing and Pap Test market revenue are grossed from Pap Tests, which have a predicted CAGR of 16.8% by 2032. Cervical Cancer Screening is the top application of these tests, with a CAGR of 18.4% in the forecast period. HVC and Pap tests are used extensively in Cervical Cancer Screening and awareness drives, government policies, and programs provide a significant demand boost.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global HPV Testing and Pap Test market expanded at a CAGR of 17.2% from 2015 to 2021. The global market is predicted to surge ahead at a CAGR of 19.3% and record sales worth US$ 15 Billion by the end of 2032, registering an absolute dollar opportunity of US$ 12 Billion from 2022 to 2032.
Cervical cancer is the 4th most common form of cancer amongst women worldwide. In 2020, there were an estimated 604,000 new cases and 342,000 related deaths. Cervical cancer is most treatable and curable if vaccinations are effective and the cancer is detected at an early stage and proper treatment is given promptly.
If detected at an early stage, the 5-year survival rate is very high at around 92%. Even cancers at later stages can be managed with proper treatment and care. The global strategy for cervical cancer elimination, endorsed by the WHO in 2020, aims for 70% of women globally to have undergone testing at regular intervals by 2030.
The policy is based on the idea that implementing this, along with other policies regarding treatment and vaccination could eliminate cervical cancer deaths in a century. According to the WHO, this could prevent around 62 million deaths. Pap testing, which tests for cell changes that could potentially be or become cervical cancer, and HPV testing, which looks for high-risk HPV are globally recommended. In recent years, demand is increasing due to increased awareness, developments in reducing costs, and government policies and programs.
Principal Consultant
There have been a number of government programs and policies that are boosting the global demand for testing. In the USA, the CDC recommends a Pap test or cytology test once every 3 years for 21-29-year-olds and a pap test every 3 years or an HPV test every 5 years, or a cotest of both Pap and HPV tests every 5 years for those over 30 years.
In China, the All-China Women's Federation and the Ministry of Health launched a dual program for screening cervical and breast cancer in rural women, at 3-year intervals. In Japan, the National Cancer Center recommends screening every 2 years. Most cities offer free or subsidized options for women of eligible age groups. In South Korea, which has a single-payer public health insurance system, eligible women over 20 years of age are provided a free screening once every 2 years.
Nearly 90% of HPV deaths occurring in 2020, occurred in low and middle-income countries; largely owing to the fact that low-resource areas often do not have the ability to provide regular screening. A commonly used method is Visual Inspection with Acetic Acid or VIA testing which involves a health worker applying dilute acetic acid to the cervix and inspecting it for visual signs of whitening with the naked eye.
This method is used despite lower accuracy in low-resource areas since it has lower cost-per-test and is convenient. Another developing technology that has the potential to raise demand in low-resource areas is the use of AI in diagnosis. A team of researchers from the National Cancer Institute (NCI) and Global Good trained an ML algorithm to use Automated Visual Evaluation (AVE) to analyze images of a cervix and identify changes that could lead to cancer. The images can be taken with even a simple camera. New developments such as training the algorithm with a more global set of images to account for geographic variations are expected to eventually raise demand.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Cervical Cancer Screening is the top application for HPV testing and Pap Testing, with a CAGR of 16.7% from 2015 to 2021. The forecasted CAGR for this category is 18.4% for the period 2022 to 2032. Neither HPV testing nor the Pap test can detect vaginal cancer on its own, but they do detect cervical cancer and pre-cancerous conditions- which are often precursors to vaginal cancer, and HPV, which increases the risk of developing vaginal cancer.
Europe is an emerging HPV Testing and Pap Test market for HPV and Pap tests. According to the European Centre for Disease Prevention and Control or the ECDC, 2.5% of all cancers in Europe are caused by HPV, and Cervical cancer is the second most common type of cancer in women of the 15 to 55 age group, after only breast cancer. Awareness drives and official programs are driving demand. For example, in the United Kingdom, the NHS provides free tests to women every 3 years if in the 25 to 29 age category and every 5 years to women over 50 years of age. The program uses an initial HPV test and an additional Pap Test for cells that test positive.
The USA contributes significantly to the HPV and Pap Tests market, with a forecasted market size of US $5.9 Billion by 2032. The American cancer society recommends screening with an HPV test or HPV/Pap cotest every 5 years from 25 years of age to 65 years, or a Pap Test every 3 years. The Centers for Disease Control provides free or low-cost screenings to women who qualify based on factors like income levels and insurance coverage under their National Breast and Cervical Cancer Early Detection Program (NBCCEDP). The HPV Testing and Pap Test market in the country is expected to garner an absolute dollar opportunity of US$ 5 Billion. The HPV Testing and Pap Test market in the USA witnessed a CAGR of 18.2% from 2015 to 2021 and is expected to continue growing, with a forecasted CAGR growing at 20.4%.
The HPV Testing and Pap Test market in the United Kingdom is expected to reach a valuation of US$ 672.7 Million by 2032. With a projected CAGR of 20.2% from 2022 to 2032, the market is expected to garner an absolute dollar opportunity of US$ 567 Million.
The HPV Testing and Pap Test market in Japan is expected to account for US$ 795 Million by 2032. Growing at a CAGR of 22.4% from 2022 to 2032, the market is likely to gross an absolute dollar opportunity of US$ 689 Million.
The HPV Testing and Pap Test market in South Korea is expected to reach a valuation of US$ 241 Million by 2032. The market from 2022 to 2032 is expected to grow at a CAGR to garner an absolute dollar opportunity of US$ 194 Million.
PAP tests are the largest contributor to HPV Testing and Pap Test market revenue, having witnessed a CAGR of 16.8% with a forecasted CAGR of 17.5% for the next decade. Their use has led to a significant decrease in Cervical Cancer deaths. However, new WHO guidelines shift to the HPV DNA-based test as preferred over the currently prevalent VIA or Pap Tests. Despite this, Pap tests, which are the historical method in use, are still useful and common. There are concerns that additional HPV testing would mean an increase in invasive procedures. A combination of both tests is now recommended, with healthcare providers and global programs choosing whether to administer one of the two or both depending on patient age, history, and availability of resources.
HPV Testing and Pap Test providers are focused on increasing the efficiency, accuracy, and affordability of their tests and harnessing new technology. The key companies operating include Abbott Laboratories, Qiagen N.V., Becton, Dickinson and Company, Quest Diagnostics, Inc., Hologic, Inc., F. Hoffmann-La Roche, Femasys, Inc., Arbor Vita Corporation, NURX, Inc., Seegene, Inc., Thermo Fisher Scientific. Inc., and bioMérieux SA
Some of the recent developments in HPV Testing and Pap Tests are as follows:
Similarly, recent developments related to companies manufacturing HPV Testing and Pap Tests have been tracked by the team at Future Market Insights, which is available in the full report.
The global HPV Testing and Pap Test market was valued at US$ 2.2 Billion in 2021.
The HPV Testing and Pap Test industry is set to witness a growth rate of 19.3% over the forecast period and be valued at US$ 15 Billion by 2032.
The HPV Testing and Pap Test market expanded by 17.2% from 2015 through 2021.
Abbott Laboratories, Qiagen N.V., Becton, Dickinson and Company, Quest Diagnostics, Inc., Hologic, Inc., F. Hoffmann-La Roche, Femasys, Inc., Arbor Vita Corporation, NURX, Inc., Seegene, Inc., Thermo Fisher Scientific. Inc., bioMérieux SA are some of the key players in the market.
The USA, United Kingdom, China, Japan, and South Korea are expected to be the key drivers of sales.
The market in the USA accounts for over 39% of the global market.
1. Executive Summary | HPV Testing and Pap Test Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2015 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ Million) Analysis, 2015 to 2021
4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Test Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Test Type, 2015 to 2021
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Test Type, 2022 to 2032
5.3.1. HPV Testing
5.3.2. Pap Test
5.4. Y-o-Y Growth Trend Analysis By Test Type, 2015 to 2021
5.5. Absolute $ Opportunity Analysis By Test Type, 2022 to 2032
6. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Application
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2015 to 2021
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2022 to 2032
6.3.1. Vaginal Cancer Screening
6.3.2. Cervical Cancer Screening
6.4. Y-o-Y Growth Trend Analysis By Application, 2015 to 2021
6.5. Absolute $ Opportunity Analysis By Application, 2022 to 2032
7. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Product Type
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2015 to 2021
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2022 to 2032
7.3.1. Instruments
7.3.2. Consumables
7.3.3. Services
7.4. Y-o-Y Growth Trend Analysis By Product Type, 2015 to 2021
7.5. Absolute $ Opportunity Analysis By Product Type, 2022 to 2032
8. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Technology
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Technology, 2015 to 2021
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Technology, 2022 to 2032
8.3.1. PCR (Polymerase Chain Reaction)
8.3.2. Immunodiagnostics
8.3.3. Other Technologies
8.4. Y-o-Y Growth Trend Analysis By Technology, 2015 to 2021
8.5. Absolute $ Opportunity Analysis By Technology, 2022 to 2032
9. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2015 to 2021
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. Asia Pacific
9.3.5. Middle East and Africa
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. USA
10.2.1.2. Canada
10.2.2. By Test Type
10.2.3. By Application
10.2.4. By Product Type
10.2.5. By Technology
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Test Type
10.3.3. By Application
10.3.4. By Product Type
10.3.5. By Technology
10.4. Key Takeaways
11. Latin America Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Test Type
11.2.3. By Application
11.2.4. By Product Type
11.2.5. By Technology
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Test Type
11.3.3. By Application
11.3.4. By Product Type
11.3.5. By Technology
11.4. Key Takeaways
12. Europe Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. Italy
12.2.1.3. France
12.2.1.4. United Kingdom
12.2.1.5. Russia
12.2.1.6. BENELUX
12.2.1.7. Rest of Europe
12.2.2. By Test Type
12.2.3. By Application
12.2.4. By Product Type
12.2.5. By Technology
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Test Type
12.3.3. By Application
12.3.4. By Product Type
12.3.5. By Technology
12.4. Key Takeaways
13. Asia Pacific Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.1.4. Rest of Asia Pacific
13.2.2. By Test Type
13.2.3. By Application
13.2.4. By Product Type
13.2.5. By Technology
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Test Type
13.3.3. By Application
13.3.4. By Product Type
13.3.5. By Technology
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Turkey
14.2.1.4. Rest of Middle East and Africa
14.2.2. By Test Type
14.2.3. By Application
14.2.4. By Product Type
14.2.5. By Technology
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Test Type
14.3.3. By Application
14.3.4. By Product Type
14.3.5. By Technology
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Test Type
15.1.2.2. By Application
15.1.2.3. By Product Type
15.1.2.4. By Technology
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Test Type
15.2.2.2. By Application
15.2.2.3. By Product Type
15.2.2.4. By Technology
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Test Type
15.3.2.2. By Application
15.3.2.3. By Product Type
15.3.2.4. By Technology
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Test Type
15.4.2.2. By Application
15.4.2.3. By Product Type
15.4.2.4. By Technology
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Test Type
15.5.2.2. By Application
15.5.2.3. By Product Type
15.5.2.4. By Technology
15.6. Italy
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2021
15.6.2.1. By Test Type
15.6.2.2. By Application
15.6.2.3. By Product Type
15.6.2.4. By Technology
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2021
15.7.2.1. By Test Type
15.7.2.2. By Application
15.7.2.3. By Product Type
15.7.2.4. By Technology
15.8. United Kingdom
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2021
15.8.2.1. By Test Type
15.8.2.2. By Application
15.8.2.3. By Product Type
15.8.2.4. By Technology
15.9. Russia
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2021
15.9.2.1. By Test Type
15.9.2.2. By Application
15.9.2.3. By Product Type
15.9.2.4. By Technology
15.10. BENELUX
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2021
15.10.2.1. By Test Type
15.10.2.2. By Application
15.10.2.3. By Product Type
15.10.2.4. By Technology
15.11. China
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2021
15.11.2.1. By Test Type
15.11.2.2. By Application
15.11.2.3. By Product Type
15.11.2.4. By Technology
15.12. Japan
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2021
15.12.2.1. By Test Type
15.12.2.2. By Application
15.12.2.3. By Product Type
15.12.2.4. By Technology
15.13. South Korea
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2021
15.13.2.1. By Test Type
15.13.2.2. By Application
15.13.2.3. By Product Type
15.13.2.4. By Technology
15.14. GCC Countries
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2021
15.14.2.1. By Test Type
15.14.2.2. By Application
15.14.2.3. By Product Type
15.14.2.4. By Technology
15.15. South Africa
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2021
15.15.2.1. By Test Type
15.15.2.2. By Application
15.15.2.3. By Product Type
15.15.2.4. By Technology
15.16. Turkey
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2021
15.16.2.1. By Test Type
15.16.2.2. By Application
15.16.2.3. By Product Type
15.16.2.4. By Technology
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Test Type
16.3.3. By Application
16.3.4. By Product Type
16.3.5. By Technology
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Abbott Laboratories
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Qiagen N.V.
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Becton, Dickinson, and Company
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Quest Diagnostics, Inc.
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Hologic, Inc.
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. F. Hoffmann-La Roche
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Femasys, Inc.
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Arbor Vita Corporation
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. NURX, Inc.
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Seegene, Inc.
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.11. Thermo Fisher Scientific, Inc.
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.12. bioMérieux SA
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
HPV Testing and Pap Test Market
